The goal and significance of the University of Pennsylvania (Penn) TL1 proposal is matched to both a national and societal need to dramatically enhance clinical and translational science (CTS). A key component of this goal is to train the next generation of research leaders of this domain. As expressed throughout our CTSA proposal, Penn is committed ?all-in? to the advancement of translational science, led by the Institute for Translation Medicine and Therapeutics (ITMAT), and within this to achieve the overarching TL1 goal of arming our trainees with the awareness, skills and resources that will position them to excel in the conduct of CTS. Ten pre-doctoral and ten post-doctoral slots are requested to support TL1 Scholars who will enroll in either Certificate (1year) or Master degree (2-3year) programs developed specifically for CTS. The structure of Penn's TL1 builds synergistically upon and integrates seamlessly with Penn's outstanding graduate and post- graduate programs, but recognizes that translational science requires a distinctive, additional knowledge and skill set. Pre-doctoral Scholars will be selected from Penn's PhD, MD/PhD and VMD/PhD research programs and MD, VMD, DMD and MNS clinical training programs. Similarly, post-doctoral Scholars will be selected from Penn's outstanding clinical (MD, VMD, DMD) residents and fellows, and research (PhD) fellows. The primary objectives of the TL1 program are: ? Recruit talented and committed trainees by promoting awareness and individual assessment; ? Develop mentored personalized trainee educational plans targeted both to discipline specific skills and professional competencies; ? Develop fundamental scientific skills and conduct mentored research in clinical and translational science; ? Advance training programs in emerging areas of translational science; ? Augment aligned professional skill sets of trainees to bolster career progression Scholars are supported by innovative cross-discipline bridges, by creating new knowledge paradigms for translation, by providing outstanding translational research facilities and cores, and through active advising and mentorship ? always with an eye toward the highest ethical standards, the essential tenants of translation, what unites our trainees as colleagues, and what distinguishes our training program and the TL1 award as a singular entity, rather than a mere collection of elements. The TL1 minimizes time-to-degree by effective use of elective units and off-hours online instruction. The TL1 emphasizes the development of individual professional development plans to support diverse career preferences. Importantly, the program is also coupled to a robust diversity and inclusion effort, and a dedicated mentoring program. In summary, Penn's TL1/CTSA approach speaks directly to each of the five key CTSA goals and builds upon existing excellence with rigor, breadth, flexibility and individuality. The educational program is led by talented and experienced Co-Program Directors and the TL1 award is seamlessly integrated with the CTSA-U and KL2 award components. Importantly, the TL1 award is the only dedicated mechanism at Penn to support pre and post-doctoral scholars in CTS.
| Riley, John S; Urwin, John W; Oliver, Edward R et al. (2018) Prenatal growth characteristics and pre/postnatal management of bronchopulmonary sequestrations. J Pediatr Surg 53:265-269 |
| Irwin, David J; Xie, Sharon X; Coughlin, David et al. (2018) CSF tau and ?-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 90:e1038-e1046 |
| Yuan, Zuo-Fei; Sidoli, Simone; Marchione, Dylan M et al. (2018) EpiProfile 2.0: A Computational Platform for Processing Epi-Proteomics Mass Spectrometry Data. J Proteome Res 17:2533-2541 |
| Morrison, Alexander H; Byrne, Katelyn T; Vonderheide, Robert H (2018) Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer 4:418-428 |
| Irwin, David J; Hurtig, Howard I (2018) The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism 8: |
| Hadar, Peter N; Kini, Lohith G; Coto, Carlos et al. (2018) Clinical validation of automated hippocampal segmentation in temporal lobe epilepsy. Neuroimage Clin 20:1139-1147 |
| Riley, John S; McClain, Lauren E; Stratigis, John D et al. (2018) Pre-Existing Maternal Antibodies Cause Rapid Prenatal Rejection of Allotransplants in the Mouse Model of In Utero Hematopoietic Cell Transplantation. J Immunol 201:1549-1557 |
| Samuels, Stephanie L; Namoc, Sisi M; Bauer, Andrew J (2018) Neonatal Thyrotoxicosis. Clin Perinatol 45:31-40 |
| Patel, Shetal A; Minn, Andy J (2018) Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity 48:417-433 |
| Samuels, Stephanie L; Surrey, Lea F; Hawkes, Colin P et al. (2018) Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort. J Clin Endocrinol Metab 103:1639-1648 |
Showing the most recent 10 out of 18 publications
